What is the appropriate workup and treatment for suspected IgG4‑related disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IgG4-Related Disease: Workup and Treatment

For suspected IgG4-related disease, initiate oral prednisolone 40 mg daily (or 0.5-0.6 mg/kg/day) for 2-4 weeks as first-line treatment after confirming diagnosis through tissue biopsy showing >10 IgG4+ plasma cells per high-power field, elevated serum IgG4, and characteristic imaging findings. 1, 2

Diagnostic Workup Algorithm

Step 1: Clinical Recognition

Look for these specific presentations:

  • Pancreatic involvement: Mass or enlargement on CT, ductal abnormalities, exocrine insufficiency
  • Biliary disease: Obstructive jaundice, cholangitis patterns on MRCP
  • Multi-organ manifestations: Salivary/lacrimal gland swelling, retroperitoneal fibrosis, aortitis, lymphadenopathy, interstitial nephritis
  • Absence of IBD (helps distinguish from PSC - IBD present in 70% of PSC vs 5.6% in IgG4-RD) 1

Step 2: Laboratory Testing

  • Serum IgG4: Elevated in 50-80% of cases, but cannot diagnose in isolation 1
    • IgG4/IgG1 ratio >0.24 improves specificity
    • IgG4 >4x upper limit of normal is highly specific
    • Critical caveat: 9-15% of PSC patients also have elevated IgG4 1
  • Check for eosinophilia, polyclonal gammopathy, complement consumption 3

Step 3: Imaging

  • MRCP is mandatory for all suspected cases 1
  • Cross-sectional imaging (CT/MRI) to assess:
    • Pancreatic abnormalities (long duct strictures >1/3 length, multifocal stricturing)
    • Biliary tree patterns (4 types described)
    • Other organ involvement
  • PET scan can identify distant organ involvement (salivary/lacrimal glands) 1

Step 4: Tissue Diagnosis (Essential)

Pursue pathological confirmation in all cases 1:

  • Endoscopic ampullary biopsy with IgG4 immunostaining (positive in 52-72% of cases) 1
  • Look for: >10 IgG4+ plasma cells per high-power field with IgG4+/IgG+ ratio >40%
  • Characteristic histology: lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis 1
  • Liver/tissue biopsy if ampullary biopsy non-diagnostic 1

Step 5: Screen for Multi-Organ Disease

Systematically evaluate for other organ involvement - this is critical for prognosis and treatment planning 1:

  • Pancreas, kidneys, retroperitoneum, lungs, salivary glands
  • Multi-organ involvement predicts higher relapse rates (>60%) 1

Treatment Protocol

Initial Therapy (First-Line)

Oral prednisolone 40 mg daily for 2-4 weeks, then taper by 5 mg weekly over 8-12 weeks 1, 2

Alternative dosing for elderly or diabetic patients: 10-20 mg daily may be effective with fewer side effects 2

Assess response at weeks 2-4 using:

  • Clinical improvement (resolution of jaundice, pain)
  • Biochemistry (liver enzymes, bilirubin)
  • Repeat imaging at weeks 4-8 1

Important: Lack of radiological improvement suggests either wrong diagnosis or fibrotic (non-inflammatory) phase 1

Maintenance Therapy (Critical to Prevent Relapse)

Relapse occurs in 60% of IgG4-SC patients and >40% of general IgG4-RD after steroid cessation 1. Therefore:

Introduce steroid-sparing immunosuppression during prednisolone taper 1, 2:

  • Azathioprine 2 mg/kg/day (most commonly used)
  • Alternatives: mycophenolate mofetil, 6-mercaptopurine
  • Continue for up to 3 years, potentially longer 2

Maintenance prednisolone 5-7.5 mg daily reduces 3-year relapse from 58% to 23% (based on randomized data in IgG4-RD) 1

Refractory or Relapsing Disease

Rituximab is the preferred treatment for:

  • Failure of first-line therapy
  • Disease flare during steroid withdrawal
  • Multi-system or complex disease 1

Dosing: 2 infusions of 1,000 mg rituximab 15 days apart, repeat every 6 months 2

  • Response rate >95% in case series 1
  • Inebilizumab (anti-CD19) is now FDA-approved and shows longer-lasting responses than rituximab 4, 5

Monitoring Strategy

Do NOT use serum IgG4 levels to monitor treatment or guide therapy 1 - it often falls with steroids but doesn't correlate with disease activity

Monitor with:

  • Clinical symptoms
  • Liver biochemistry
  • Repeat imaging for mass lesions and cholangiopathy
  • Regular follow-up for relapse detection 3

Critical Pitfalls to Avoid

  1. Never diagnose IgG4-RD on serum IgG4 alone - requires comprehensive workup including histology 1

  2. Always exclude malignancy - up to 8% of presumed hilar cholangiocarcinoma cases are actually IgG4-SC 1

  3. Don't stop at initial steroid response - the high relapse rate mandates maintenance immunosuppression 1, 2

  4. Refer complex cases to specialist centers for multidisciplinary review, especially with multi-organ involvement or suspected malignancy 1

  5. Distinguish from PSC - presence of IBD, younger age, and lack of steroid response favor PSC over IgG4-RD 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.